 Lineage Cell Therapeutics, Inc. NYSE American and TASE: LCTX, a clinical-stage cell therapy company which manufactures and transplants specific cell types to treat diseases and serious medical conditions, today announced that it has restarted patient enrollment in a Phase 12a clinical study of its lead product candidate, OpRegen, a retinal pigment epithelium RPE cell transplant therapy currently in development for the treatment of dry age-related macular degeneration AMD, following a temporary pause in enrollment as a result of the COVID-19 pandemic. The first patient dosed in the re-start was at Cincinnati Eye Institute CEI under the direction of principal investigator Christopher D. Riemann, M.D., Vitreoretinal Surgeon and Fellowship Director, CEI and University of Cincinnati School of Medicine. CEI is a global leader in ophthalmology research and a clinical site where local health and safety regulations recently enabled and cleared clinical study recruitment and treatment. The patient enrolled at CEI was administered Lineages new thaw-and-inject formulation of OpRegen with Gyroscope Therapeutics Orbit Subretinal Delivery System SDS. The Company anticipates that it will complete enrollment of the last 3 patients in Cohort 4 of the OpRegen clinical study in the third quarter of 2020. 